Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
glycolate oxidase
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "glycolate oxidase" in MCE Product Catalog:
1
Research Areas:
Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1) .
1
1 Cited Publications
Research Areas:
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
Cat. No.: HY-W088011B
CAS No.: 2836-32-0
Synonyms: Sodium hydroxyacetate, 98%
Cat. No.: HY-W176012
CAS No.: 330977-65-6
Target:
Research Areas:
Glycolate oxidase-IN-1(compound 26), a salicylic acid derivative, is a glycolate oxidase (GO) inhibitor with an IC50 of 38.2 μM. Glycolate oxidase-IN-1 has the ability to reduce oxalate production in hyperoxalate hepatocytes and can be used in the study of primary hyperoxaluria type 1 (PH1) .
Cat. No.: HY-22166
CAS No.: 77529-42-1
Target:
Research Areas:
Glycolic acid oxidase inhibitor 1 is a glycolate oxidase inhibitor, extracted from patent EP0021228A1, in Table IV.
Cat. No.: HY-148610
CAS No.: 893739-96-3
Target:
Research Areas:
LDH-IN-2, a salicylic acid derivative, is an inhibitor of glycolate oxidase (GO). LDH-IN-2 decreases oxalate output in hyperoxaluric hepatocytes. LDH-IN-2 can be used for research of primary hyperoxaluria type 1 (PH1) .
Cat. No.: HY-156648
CAS No.: 2408241-62-1
Target:
Research Areas:
Vamagloxistat is glycolate oxidase inhibitor, used to inhibit hyperoxaluria and kidney stones .
Cat. No.: HY-P70932
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: HAO1; glycolate oxidase 1; Prev. GOX1; HAOX1; GOX; GO; Hydroxyacid oxidase (glycolate oxidase) 1; Alternative Protein HAO1; (S)-2-Hydroxy-Acid oxidase; glycolate oxidase; 2-Hydroxyacid oxidase 1; Hydroxyacid oxidase 1; Glyoxylate oxidase
Species:
Human
Source:
E. coli
Cat. No.: HY-P71655
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: HAO1; glycolate oxidase 1; Prev. GOX1; HAOX1; GOX; GO; Hydroxyacid oxidase (glycolate oxidase) 1; Alternative Protein HAO1; (S)-2-Hydroxy-Acid oxidase; glycolate oxidase; 2-Hydroxyacid oxidase 1; Hydroxyacid oxidase 1; Glyoxylate oxidase
Species:
Mouse
Source:
E. coli
Cat. No.: HY-156648A
CAS No.: 2667602-26-6
Target:
Research Areas:
Vamagloxistat (sodium) is glycolate oxidase inhibitor, used to inhibit hyperoxaluria and kidney stones .
Cat. No.: HY-180992
Target:
Research Areas:
Dual GO/LDHA-IN-1 is an orally available dual inhibitor targeting glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), with Ki values of 390 nM and 40 nM, respectively. Dual GO/LDHA-IN-1 reduces hepatic LDHA levels, urinary oxalate excretion, and renal calcium-oxalate crystal deposition. Dual GO/LDHA-IN-1 is applicable for research on primary hyperoxaluria type 1 .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
